Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-03-18
2008-03-18
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000
Reexamination Certificate
active
10446218
ABSTRACT:
The invention provides methods of downregulating mRNA encoding osteopontin comprising administering to a cell or mammal an amount of astrogorgiadiol effective to downregulate production of mRNA encoding osteopontin. The invention also provides methods of treating osteoporosis and autoimmune disease comprising administering to a patient in need of such treatment a therapeutically effective amount of astrogorgiadiol. Pharmaceutical compositions comprising astrogorgiadiol and a pharmaceutically acceptable carrier or diluent are also provided.
REFERENCES:
Fusetani et al., Tetrahedron Letters, 1989;39(50):7079-7082.
Merck Index, 10thed., 1983, monograph 212, pp. 34-35.
Taber, D.F. et al., J. Org. Chem. 2001, 66, 944-953; “Synthesis of (-)-Astrogorgiadiol”.
Taber, D.F. et al., J. Org. Chem. Jul. 12, 2002, 67, 4821-4827; “Synthesis of (-)-Calicoferol B” (published on Web Jun. 13, 2002).
Farach-Carson, M.C. et al., American Physiological Society,1993, 265, F705-F711; “22-Osacalcitrol: dissection of 1,25(OH)2D3receptor-mediated and Ca2+entry-stimulating pathways”.
Fusetani et al., Tetrahedron Letters 1989, 30, 7079-7082, “Astrogorgiadiol and astrogorgin, inhibitors of cell division in fertilized starfish eggs, from a gorgonian”, (Abstract).
Chabas D. et al., Science 2001, 294, 1731-1735, “The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease”.
Forton, et al., Human Mutation 2002, Mutation in Brief #496 Online, “An Osteopontin (SPP1) Polymorphism is Associated with Systemic Lupus Erythematosus”.
Yoshitake, H. et al., Proc. Nat'l Acad. Sci. USA 1999, 96, 8156-8160, “Osteopontin-deficient mice are resistant to ovariectomy-induced bone resporption”.
Farach-Carson Mary C.
Malcolm Scott C.
Taber Douglass F.
Xu Yihuan
Hui San-Ming
RatnerPrestia
University of Delaware
LandOfFree
Treatment of osteoporosis and autoimmune disease with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of osteoporosis and autoimmune disease with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of osteoporosis and autoimmune disease with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3934272